New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study ...
MetaVia ( (MTVA)) has provided an announcement. On January 5, 2026, MetaVia reported positive, statistically significant data from the extended eight-week, non-titrated 48 mg multiple ascending dose ...